Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-985521 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A Cohort 1 | EXPERIMENTAL | - |
| Part A Cohort 2 | EXPERIMENTAL | - |
| Part A Cohort 3 | EXPERIMENTAL | - |
| Part A Cohort 4 | EXPERIMENTAL | - |
| Part A Cohort 5 | EXPERIMENTAL | - |
| Part A Cohort 6 | EXPERIMENTAL | - |
| Part B Cohort 7 | EXPERIMENTAL | - |
| Part B Cohort 8 | EXPERIMENTAL | - |
| Part B Cohort 9 | EXPERIMENTAL | - |
| Part B Cohort 10 | EXPERIMENTAL | - |
| Part B Cohort 11 | EXPERIMENTAL | - |
| Part C | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-985521 | DRUG | Specified dose on specified days. |
| Placebo | OTHER | Specified dose on specified days |
Inclusion Criteria: * Participants must be healthy males and females (assigned at birth) who are not of childbearing potential, with no clinically significant abnormalities in medical history, physical exam, ECG, or lab tests. * Participants must have a body mass index (BMI) between 18 and 32 kg/m²...
BMS-985521 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development to evaluate its safety, tolerability, and drug levels in the body. The drug is not approved for any medical condition and is still in early-stage clinical testing.
BMS-985521 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting a Phase 1 clinical trial to assess the drug's safety and pharmacokinetics in healthy participants.
BMS-985521 is in Phase 1 clinical development. It is an investigational drug being studied in healthy volunteers to evaluate its safety, tolerability, and drug levels. The drug is not FDA approved and remains in early-stage clinical testing.
BMS-985521 is being studied in a Phase 1 clinical trial with the identifier NCT07283263. This trial is recruiting 106 healthy participants in the United States and is designed to evaluate the safety, tolerability, and drug levels of BMS-985521. The study is randomized, double-blind, and controlled.
BMS-985521 and BMS-986521 are different drug names. The clinical trial NCT07283263 is titled 'A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants,' which suggests the drug being studied is BMS-986521, not BMS-985521. The two names are not interchangeable.